These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 20484426)
21. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143 [TBL] [Abstract][Full Text] [Related]
22. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318 [TBL] [Abstract][Full Text] [Related]
23. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer. Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108 [TBL] [Abstract][Full Text] [Related]
24. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592 [TBL] [Abstract][Full Text] [Related]
25. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]
26. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020 [TBL] [Abstract][Full Text] [Related]
27. [18FDG] PET-CT-based intensity-modulated radiotherapy treatment planning of head and neck cancer. El-Bassiouni M; Ciernik IF; Davis JB; El-Attar I; Reiner B; Burger C; Goerres GW; Studer GM Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):286-93. PubMed ID: 17707283 [TBL] [Abstract][Full Text] [Related]
28. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. Arens AI; Troost EG; Hoeben BA; Grootjans W; Lee JA; Grégoire V; Hatt M; Visvikis D; Bussink J; Oyen WJ; Kaanders JH; Visser EP Eur J Nucl Med Mol Imaging; 2014 May; 41(5):915-24. PubMed ID: 24346414 [TBL] [Abstract][Full Text] [Related]
29. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667 [TBL] [Abstract][Full Text] [Related]
30. Tumor volume delineation in head and neck cancer with 18-fluor-fluorodeoxiglucose positron emission tomography: adaptive thresholding method applied to primary tumors and metastatic lymph nodes. Perez-Romasanta LA; Bellon-Guardia M; Torres-Donaire J; Lozano-Martin E; Sanz-Martin M; Velasco-Jimenez J Clin Transl Oncol; 2013 Apr; 15(4):283-93. PubMed ID: 22865325 [TBL] [Abstract][Full Text] [Related]
31. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Vees H; Senthamizhchelvan S; Miralbell R; Weber DC; Ratib O; Zaidi H Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):182-93. PubMed ID: 18818918 [TBL] [Abstract][Full Text] [Related]
32. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. Yue J; Chen L; Cabrera AR; Sun X; Zhao S; Zheng F; Han A; Zheng J; Teng X; Ma L; Ma Y; Han D; Zhao X; Mu D; Yu J; Li Y J Nucl Med; 2010 Apr; 51(4):528-34. PubMed ID: 20237030 [TBL] [Abstract][Full Text] [Related]
33. Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation. Wang K; Heron DE; Clump DA; Flickinger JC; Kubicek GJ; Rwigema JC; Ferris RL; Ohr JP; Quinn AE; Ozhasoglu C; Branstetter BF Radiother Oncol; 2013 Jan; 106(1):90-5. PubMed ID: 23333021 [TBL] [Abstract][Full Text] [Related]
34. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. Dibble EH; Alvarez AC; Truong MT; Mercier G; Cook EF; Subramaniam RM J Nucl Med; 2012 May; 53(5):709-15. PubMed ID: 22492732 [TBL] [Abstract][Full Text] [Related]
35. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. Hoeben BA; Troost EG; Span PN; van Herpen CM; Bussink J; Oyen WJ; Kaanders JH J Nucl Med; 2013 Apr; 54(4):532-40. PubMed ID: 23345303 [TBL] [Abstract][Full Text] [Related]
36. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292 [TBL] [Abstract][Full Text] [Related]
37. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. Been LB; Suurmeijer AJ; Elsinga PH; Jager PL; van Ginkel RJ; Hoekstra HJ J Nucl Med; 2007 Mar; 48(3):367-72. PubMed ID: 17332613 [TBL] [Abstract][Full Text] [Related]
38. Monitoring tumor proliferative response to radiotherapy using (18)F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67. Fatema CN; Zhao S; Zhao Y; Murakami M; Yu W; Nishijima K; Tamaki N; Kitagawa Y; Kuge Y Ann Nucl Med; 2013 May; 27(4):355-62. PubMed ID: 23417197 [TBL] [Abstract][Full Text] [Related]
39. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Choi W; Lee SW; Park SH; Ryu JS; Oh SJ; Im KC; Choi EK; Kim JH; Jung SH; Kim S; Ahn SD Radiother Oncol; 2010 Nov; 97(2):176-82. PubMed ID: 20855118 [TBL] [Abstract][Full Text] [Related]
40. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Schinagl DA; Span PN; Oyen WJ; Kaanders JH Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1449-58. PubMed ID: 21461734 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]